Details for Patent: 8,114,833
✉ Email this page to a colleague
Which drugs does patent 8,114,833 protect, and when does it expire?
Patent 8,114,833 protects OZEMPIC, SAXENDA, and VICTOZA, and is included in three NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-five patent family members in nineteen countries.
Summary for Patent: 8,114,833
| Title: | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| Abstract: | The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation. |
| Inventor(s): | Pedersen; Tina Bjeldskov (Smorum, DK), Bonde; Claude (Lyngby, DK), Engelund; Dorthe Kot (Holte, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 11/435,977 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,114,833 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Use; Device; |
Drugs Protected by US Patent 8,114,833
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,114,833
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2003 01719 | Nov 20, 2003 |
International Family Members for US Patent 8,114,833
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004290862 | ⤷ Try a Trial | |||
| Brazil | PI0416743 | ⤷ Try a Trial | |||
| Canada | 2545034 | ⤷ Try a Trial | |||
| China | 102784386 | ⤷ Try a Trial | |||
| China | 104826116 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
